DK1003553T3 - Anvendelsen af angiostatiske steroider i fotodynamisk terapi - Google Patents

Anvendelsen af angiostatiske steroider i fotodynamisk terapi

Info

Publication number
DK1003553T3
DK1003553T3 DK98931367T DK98931367T DK1003553T3 DK 1003553 T3 DK1003553 T3 DK 1003553T3 DK 98931367 T DK98931367 T DK 98931367T DK 98931367 T DK98931367 T DK 98931367T DK 1003553 T3 DK1003553 T3 DK 1003553T3
Authority
DK
Denmark
Prior art keywords
photodynamic therapy
angiostatic steroids
angiostatic
steroids
steriod
Prior art date
Application number
DK98931367T
Other languages
English (en)
Inventor
Abbot F Clark
Original Assignee
Alcon Mfg Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Mfg Ltd filed Critical Alcon Mfg Ltd
Application granted granted Critical
Publication of DK1003553T3 publication Critical patent/DK1003553T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027—Azides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98931367T 1997-07-16 1998-06-18 Anvendelsen af angiostatiske steroider i fotodynamisk terapi DK1003553T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/895,184 US5770592A (en) 1991-11-22 1997-07-16 Prevention and treatment of ocular neovascularization using angiostatic steroids

Publications (1)

Publication Number Publication Date
DK1003553T3 true DK1003553T3 (da) 2004-09-20

Family

ID=25404127

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98931367T DK1003553T3 (da) 1997-07-16 1998-06-18 Anvendelsen af angiostatiske steroider i fotodynamisk terapi

Country Status (13)

Country Link
US (2) US5770592A (da)
EP (1) EP1003553B1 (da)
JP (1) JP2001510170A (da)
AT (1) ATE274356T1 (da)
AU (1) AU734195B2 (da)
BR (1) BR9811012A (da)
CA (1) CA2296558A1 (da)
DE (1) DE69825906T2 (da)
DK (1) DK1003553T3 (da)
ES (1) ES2224412T3 (da)
HK (1) HK1028952A1 (da)
PT (1) PT1003553E (da)
WO (1) WO1999003503A1 (da)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040089A1 (en) * 1999-01-05 2000-07-13 Massachusetts Eye And Ear Infirmary Targeted transscleral controlled release drug delivery to the retina and choroid
EP1131100B1 (en) * 1999-01-15 2003-03-12 Light Sciences Corporation Therapeutic compositions for metabolic bone disorders or bone metastases comprising a photosensitizer and a bisphosphonate
CA2356532A1 (en) 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
PT1221917E (pt) 1999-10-21 2005-04-29 Alcon Inc Dispositivo para ministrar medicamentos
DE60018777T2 (de) 1999-10-21 2006-02-02 Alcon Inc. Medikamentenversorgung der sub-tenon
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
AU2001234979B2 (en) * 2000-02-10 2006-07-27 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
EP1570859A3 (en) * 2000-03-24 2008-04-02 Novartis AG Improved treatment of neovascularization
PL359027A1 (en) 2000-03-24 2004-08-23 Novartis Ag Improved treatment of neovascularization
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
ATE377404T1 (de) * 2000-05-19 2007-11-15 Michael S Berlin Laserapplikationssystem und methode zur verwendung im auge
US8679089B2 (en) 2001-05-21 2014-03-25 Michael S. Berlin Glaucoma surgery methods and systems
EP1387671A1 (en) 2001-05-03 2004-02-11 MASSACHUSETTS EYE & EAR INFIRMARY Implantable drug delivery device and use thereof
ES2278936T3 (es) 2001-07-23 2007-08-16 Alcon, Inc. Dispositivo de administracion de farmacos oftalmicos.
MXPA03011610A (es) * 2001-07-23 2004-07-01 Alcon Inc Dispositivo para la administracion de farmacos oftalmicos.
JP4490689B2 (ja) * 2001-10-03 2010-06-30 メルク・シャープ・エンド・ドーム・コーポレイション アンドロゲン受容体調節剤としてのアンドロスタン１７β−カルボキサミド類
IL161327A0 (en) * 2001-11-09 2004-09-27 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
US6723750B2 (en) 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
AU2003217531A1 (en) * 2002-05-02 2003-11-17 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
ATE547416T1 (de) 2002-07-24 2012-03-15 Dermira Canada Inc Pyrazolylbenzothiazolderivate und deren verwendung als therapeutische mittel
US6806364B2 (en) * 2002-07-29 2004-10-19 Ast Products, Inc. Ophthalmic compositions
US6828356B2 (en) * 2002-07-29 2004-12-07 Ast Products, Inc. Preparation of ophthalmic compositions
AU2003259301A1 (en) * 2002-07-29 2004-02-16 Ast Products, Inc. Ophtalmic compositions
US20040127472A1 (en) * 2002-08-05 2004-07-01 Jerdan Janice A. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
DE10238310A1 (de) * 2002-08-21 2004-03-04 Erich Jaeger Gmbh Elektrodenanordnung
CA2500877A1 (en) * 2002-10-03 2004-04-15 Light Sciences Corporation Excitation of photoreactive compounds in eye tissue
US20060167435A1 (en) * 2003-02-18 2006-07-27 Adamis Anthony P Transscleral drug delivery device and related methods
RU2005129278A (ru) * 2003-02-20 2006-01-27 Алькон, Инк. (Ch) Препаративные глюкокортикоиды для лечения патологического ангиогенеза глаз
AU2004212895A1 (en) * 2003-02-20 2004-09-02 Alcon, Inc. Use of steroids to treat ocular disorders
JP2007500250A (ja) * 2003-06-13 2007-01-11 アルコン，インコーポレイテッド 病的な眼の新脈管形成を処置するための非ステロイド性抗炎症剤の処方物
US20070059381A1 (en) * 2003-06-20 2007-03-15 Barker Ronnie C Treatment of amd with combination of ingredients
ZA200508654B (en) * 2003-07-10 2007-01-31 Alcon Inc Ophthalmic drug delivery device
CN1882338A (zh) * 2003-09-18 2006-12-20 马库赛特公司 经巩膜递送
MXPA06003185A (es) * 2003-09-23 2006-06-23 Alcon Inc Formulaciones de acetonuro de triamcinolona y de acetato de anecotarve para inyeccion.
WO2005072744A1 (ja) * 2004-02-02 2005-08-11 Yuichi Kaji 硝子体の可視化剤
EP1720874A4 (en) * 2004-02-24 2010-03-03 Bioaxone Therapeutique Inc SUBSTITUTED PIPERIDINE DERIVATIVES IN POSITION 4
US20050239760A1 (en) * 2004-04-23 2005-10-27 Alcon, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
CA2581126A1 (en) 2004-09-24 2006-04-06 Rfe Pharma Llc Carboxy-amido-triazoles for the localized treatment of ocular diseases
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
US20060258698A1 (en) * 2005-02-09 2006-11-16 Sreenivasu Mudumba Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
EP2292672B1 (en) 2005-05-25 2018-05-09 CIS Pharma AG Biocompatible polymers and co-polymers comprising amino acids in the side chain
EP2446887A3 (en) * 2005-07-12 2012-08-15 DMI Biosciences, Inc. Use of danazol for the treatment of Alzheimer's disease
CN101267779A (zh) 2005-07-27 2008-09-17 福罗里达大学研究基金会有限公司 使用热休克治疗眼睛疾病
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
PE20080035A1 (es) 2005-09-07 2008-01-30 Amgen Fremont Inc Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
US7758778B2 (en) * 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US20070134244A1 (en) * 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis
US20080125406A1 (en) * 2005-10-14 2008-05-29 Robin Alan L Method for Treating Primary and Secondary Forms of Glaucoma
AU2006304553A1 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Method for treating primary and secondary forms of glaucoma
EP1956906A4 (en) 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
PL1968594T3 (pl) 2005-11-29 2011-03-31 Glaxosmithkline Llc Leczenie zaburzeń neowaskularyzacyjnych oka, takich jak zwyrodnienie plamki żółtej, rozszerzenie naczyń siatkówki w zespole Hippla i Lindaua, zapalenie błony naczyniowej oka i obrzęk plamki
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
US20090181933A1 (en) * 2008-01-11 2009-07-16 Bingaman David P Use of steroids to treat persons suffering from ocular disorders
EP2259833A1 (en) 2008-03-05 2010-12-15 Ivantis, INC. Methods and apparatus for treating glaucoma
HUE046243T2 (hu) * 2008-05-28 2020-02-28 Reveragen Biopharma Inc Nem-hormonális NF-KB szteroid modulátorok betegség kezelésére
US8632511B2 (en) 2009-05-06 2014-01-21 Alcon Research, Ltd. Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device
IN2012DN00352A (da) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
BRPI1010086A2 (pt) * 2009-06-22 2018-02-06 Dmi Acquisition Corp método e produtos para tratamento de doenças
PT2554171E (pt) 2009-06-22 2014-11-06 Ampio Pharmaceuticals Inc Método para o tratamento de doenças
WO2011006078A1 (en) 2009-07-09 2011-01-13 Ivantis, Inc. Single operator device for delivering an ocular implant
CA2766192C (en) 2009-07-09 2017-10-24 Ivantis, Inc. Ocular implants for residing partially in schlemm's canal
US20120232102A1 (en) 2009-09-30 2012-09-13 Chun-Fang Xu Methods Of Administration And Treatment
US8177747B2 (en) 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
EP2556083A4 (en) 2010-04-05 2013-12-04 Validus Biopharma Inc NONHORMONAL STEROID MODULATORS OF NF-KAPPA-B FOR DISEASE TREATMENT
US20120283557A1 (en) 2011-05-05 2012-11-08 Berlin Michael S Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses
AU2012271728B2 (en) 2011-06-14 2016-10-20 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
AU2012325341B2 (en) 2011-10-19 2017-01-05 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
EP2785346A4 (en) 2011-11-30 2015-04-29 Bikam Pharmaceuticals Inc OPSINBINDING LIGANDS, COMPOSITIONS THEREOF, AND METHOD OF USE THEREOF
AU2012346537A1 (en) 2011-12-01 2014-07-17 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
WO2014085450A1 (en) 2012-11-28 2014-06-05 Ivantis, Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
AU2013361338A1 (en) 2012-12-19 2015-08-06 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
WO2016011056A1 (en) 2014-07-14 2016-01-21 Ivantis, Inc. Ocular implant delivery system and method
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
WO2017004205A1 (en) 2015-06-29 2017-01-05 Reveragen Biopharma, Inc. NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE
CN108135470B (zh) 2015-08-14 2021-03-09 伊万提斯公司 具有压力传感器和输送***的眼部植入物
US11938058B2 (en) 2015-12-15 2024-03-26 Alcon Inc. Ocular implant and delivery system
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
WO2019014322A1 (en) 2017-07-11 2019-01-17 BioAxone BioSciences, Inc. KINASE INHIBITORS FOR THE TREATMENT OF DISEASES
AU2019223946B2 (en) 2018-02-22 2021-05-20 Alcon Inc. Ocular implant and delivery system
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
EP4274529A1 (en) 2021-01-11 2023-11-15 Alcon Inc. Systems and methods for viscoelastic delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
WO1991019731A1 (en) * 1990-06-11 1991-12-26 The Upjohn Company Steroids which inhibit angiogenesis
CA2185644C (en) * 1994-03-14 2011-04-12 Joan W. Miller Use of green porphyrins in ocular diagnosis and therapy

Also Published As

Publication number Publication date
WO1999003503A1 (en) 1999-01-28
BR9811012A (pt) 2000-10-17
CA2296558A1 (en) 1999-01-28
EP1003553B1 (en) 2004-08-25
ATE274356T1 (de) 2004-09-15
US6297228B1 (en) 2001-10-02
EP1003553A1 (en) 2000-05-31
DE69825906T2 (de) 2005-09-01
DE69825906D1 (de) 2004-09-30
ES2224412T3 (es) 2005-03-01
PT1003553E (pt) 2004-10-29
HK1028952A1 (en) 2001-03-16
AU734195B2 (en) 2001-06-07
AU8151598A (en) 1999-02-10
JP2001510170A (ja) 2001-07-31
US5770592A (en) 1998-06-23

Similar Documents

Publication Publication Date Title
DK1003553T3 (da) Anvendelsen af angiostatiske steroider i fotodynamisk terapi
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
CO4340688A1 (es) Derivados de quinazolina y procedimientos de uso de los mismos, como agentes contra el cancer, en los mamiferos.
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
HUS1500001I1 (hu) ET743 alkalmazása kombinációs terápiában dexametazollal rákbetegség kezelésére
TR200102711T2 (tr) Kriz halindeki başağrılarının iyileştirilmesinde kullanıma yönelik antikonvülsan türevler
CR7330A (es) Procedimiento para tratar enfermedades neovasculares oculares
TR200201322T2 (tr) H1 antagonistleri ve güvenli bir steroid'in göz sağlık koşullarının tedavisi için kullanımı
DK0837935T3 (da) Den 3'-ikke-translaterede region af det humane prohibitin-gen
TR199901104T2 (xx) Farmas�tik bile�ikler.
ATE442861T1 (de) Gegen antikörper gerichtete photodynamische therapie
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
DE69533873D1 (de) Krebstherapie mit lymphotoxin
DK0971710T3 (da) Anvendelse af chelerythrin og stråling til tumorterapi
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
DE69710333D1 (de) Cyclopentan(en)säure-2-alkenyl-derivate als therapeutika in der behandlung der okulären hypertonie
DK1131073T3 (da) Anvendelse af staurosporinderivater til behandling af okulære neovaskulære sygdomme
DK0983084T3 (da) Anvendelse af hyaluronidase til fremstilling af et öjenpræparat til flydendegörelse af glaslegemet i behandlingen af öjenlidelser
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
DK0900085T3 (da) Behandling af overdreven aggression med olanzapin
PT1169026E (pt) Utilizacao de activadores de ap-1 no tratamento do glaucoma e da hipertensao ocular
MXPA02000485A (es) 2-amino-benzoxazinonas para el tratamiento del virus de herpes simple.